Baseline biomarkers for PFS in relapsed/refractory CLL treated with novel agents
| Biomarker . | Venetoclax . | Ibrutinib . | Idelalisib . | Duvelisib . |
|---|---|---|---|---|
| 17p13 deletion/TP53 mutation | Inferior PFS | Inferior PFS | No effect on PFS | Unknown10 |
| Confirmed in independent cohorts1,2 | Confirmed in independent cohorts3-8 | Lack of independent validation studies9 | ||
| IGHV unmutated | Inferior PFS | No impact on PFS | No effect on PFS | Unknown10 |
| Not confirmed in independent cohorts1,2 | Confirmed in independent cohorts7,8 | Lack of independent validation studies9 | ||
| Bulky lymph nodes | Inferior PFS | No effect on PFS | Unknown9 | Unknown10 |
| Lack of independent validation studies1,2 | Confirmed in independent cohorts4,6-8 | |||
| Number of prior therapies | No effect on PFS | Inferior PFS | Unknown9 | Unknown10 |
| Lack of independent validation studies1,2 | Confirmed in independent cohorts3,4,6-8 | |||
| Elevated bate-2-microglobulin | Unknown1,2 | Inferior PFS | Unknown9 | Unknown10 |
| Not validated in independent cohorts7 | ||||
| Complex karyotype | No effect on PFS | No effect on PFS | Unknown9 | Unknown10 |
| Lack of independent validation studies1,2 | Not validated in independent cohorts5,7,8 | |||
| NOTCH1 mutation | Inferior PFS | No effect on PFS | Unknown9 | Unknown10 |
| Not validated in independent cohorts1,2 | Not validated in independent cohorts8 |
| Biomarker . | Venetoclax . | Ibrutinib . | Idelalisib . | Duvelisib . |
|---|---|---|---|---|
| 17p13 deletion/TP53 mutation | Inferior PFS | Inferior PFS | No effect on PFS | Unknown10 |
| Confirmed in independent cohorts1,2 | Confirmed in independent cohorts3-8 | Lack of independent validation studies9 | ||
| IGHV unmutated | Inferior PFS | No impact on PFS | No effect on PFS | Unknown10 |
| Not confirmed in independent cohorts1,2 | Confirmed in independent cohorts7,8 | Lack of independent validation studies9 | ||
| Bulky lymph nodes | Inferior PFS | No effect on PFS | Unknown9 | Unknown10 |
| Lack of independent validation studies1,2 | Confirmed in independent cohorts4,6-8 | |||
| Number of prior therapies | No effect on PFS | Inferior PFS | Unknown9 | Unknown10 |
| Lack of independent validation studies1,2 | Confirmed in independent cohorts3,4,6-8 | |||
| Elevated bate-2-microglobulin | Unknown1,2 | Inferior PFS | Unknown9 | Unknown10 |
| Not validated in independent cohorts7 | ||||
| Complex karyotype | No effect on PFS | No effect on PFS | Unknown9 | Unknown10 |
| Lack of independent validation studies1,2 | Not validated in independent cohorts5,7,8 | |||
| NOTCH1 mutation | Inferior PFS | No effect on PFS | Unknown9 | Unknown10 |
| Not validated in independent cohorts1,2 | Not validated in independent cohorts8 |